Low Dose Naltrexone and ALA Being Used For Cancer and MS
Posted May 26 2009 10:04pm
Mercola is highlighting interviews with Dr. Burton M. Berkson who has been successfully using LDN and ALA on terminal cancer patients, around half of which are surviving.
"However, more recently, researchers have discovered that at very low dosages (3 to 4.5 mg), naltrexone has immunomodulating properties that may be able to successfully treat cancer malignancies, and a wide range of autoimmune diseases like rheumatoid arthritis, multiple sclerosis (MS), Parkinson’s, fibromyalgia, and Crohn’s disease, just to name a few.
Added benefits include its low-cost, and few, if any, of the detrimental side effects you normally experience with pharmaceutical drugs.